These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 25985864)

  • 21. Strategies for the management of patients with obesity.
    Hamilton M
    Treat Endocrinol; 2002; 1(1):21-36. PubMed ID: 15765618
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.
    Lundgren JR; Janus C; Jensen SBK; Juhl CR; Olsen LM; Christensen RM; Svane MS; Bandholm T; Bojsen-Møller KN; Blond MB; Jensen JB; Stallknecht BM; Holst JJ; Madsbad S; Torekov SS
    N Engl J Med; 2021 May; 384(18):1719-1730. PubMed ID: 33951361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.
    Gadde KM; Allison DB; Ryan DH; Peterson CA; Troupin B; Schwiers ML; Day WW
    Lancet; 2011 Apr; 377(9774):1341-52. PubMed ID: 21481449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New-generation anti-obesity drugs: naltrexone/bupropion and liraglutide. An update for endocrinologists and nutritionists.
    Barrea L; Pugliese G; Muscogiuri G; Laudisio D; Colao A; Savastano S
    Minerva Endocrinol; 2020 Jun; 45(2):127-137. PubMed ID: 32643356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and Safety of Liraglutide 3.0 mg in Patients with Overweight and Obese with or without Diabetes: A Systematic Review and Meta-Analysis.
    Konwar M; Bose D; Jaiswal SK; Maurya MK; Ravi R
    Int J Clin Pract; 2022; 2022():1201977. PubMed ID: 35936066
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liraglutide: an injectable option for the management of obesity.
    Clements JN; Shealy KM
    Ann Pharmacother; 2015 Aug; 49(8):938-44. PubMed ID: 25986009
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Investigational glucagon-like peptide-1 agonists for the treatment of obesity.
    Tomlinson B; Hu M; Zhang Y; Chan P; Liu ZM
    Expert Opin Investig Drugs; 2016 Oct; 25(10):1167-79. PubMed ID: 27563838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study.
    Wadden TA; Hollander P; Klein S; Niswender K; Woo V; Hale PM; Aronne L;
    Int J Obes (Lond); 2013 Nov; 37(11):1443-51. PubMed ID: 23812094
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
    Davies MJ; Bergenstal R; Bode B; Kushner RF; Lewin A; Skjøth TV; Andreasen AH; Jensen CB; DeFronzo RA;
    JAMA; 2015 Aug; 314(7):687-99. PubMed ID: 26284720
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Greenway FL; Fujioka K; Plodkowski RA; Mudaliar S; Guttadauria M; Erickson J; Kim DD; Dunayevich E;
    Lancet; 2010 Aug; 376(9741):595-605. PubMed ID: 20673995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome.
    Papaetis GS; Filippou PK; Constantinidou KG; Stylianou CS
    Clin Drug Investig; 2020 Aug; 40(8):695-713. PubMed ID: 32583294
    [TBL] [Abstract][Full Text] [Related]  

  • 32. liraglutide (SAXENDA⁰) and obesit. Still no satisfactory weight loss drugs.
    Prescrire Int; 2016 Jan; 25(167):5-8. PubMed ID: 26942248
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial.
    Papamargaritis D; Al-Najim W; Lim J; Crane J; Lean M; le Roux C; McGowan B; O'Shea D; Webb D; Wilding J; Davies MJ
    BMJ Open; 2020 Feb; 10(2):e034137. PubMed ID: 32060156
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exposure-response analyses of liraglutide 3.0 mg for weight management.
    Wilding JP; Overgaard RV; Jacobsen LV; Jensen CB; le Roux CW
    Diabetes Obes Metab; 2016 May; 18(5):491-9. PubMed ID: 26833744
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis.
    Barnett AH; Arnoldini S; Hunt B; Subramanian G; Hoxer CS
    Diabetes Obes Metab; 2018 Aug; 20(8):1921-1927. PubMed ID: 29652101
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial.
    Frøssing S; Nylander M; Chabanova E; Frystyk J; Holst JJ; Kistorp C; Skouby SO; Faber J
    Diabetes Obes Metab; 2018 Jan; 20(1):215-218. PubMed ID: 28681988
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of Sinetrol-XPur on Weight and Body Fat Reduction in Overweight or Obese Adults: A 12-Week, Randomized, Double-Blind, Parallel, Placebo-Controlled Trial.
    Park SJ; Sharma A; Bae MH; Sung HC; Kim NK; Sung E; Lee HJ
    J Med Food; 2020 Mar; 23(3):335-342. PubMed ID: 32130058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Routine clinical use of liraglutide 3 mg for the treatment of obesity: Outcomes in non-surgical and bariatric surgery patients.
    Suliman M; Buckley A; Al Tikriti A; Tan T; le Roux CW; Lessan N; Barakat M
    Diabetes Obes Metab; 2019 Jun; 21(6):1498-1501. PubMed ID: 30768836
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome.
    Tzotzas T; Karras SN; Katsiki N
    Curr Vasc Pharmacol; 2017; 15(3):218-229. PubMed ID: 28003008
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.